Insulet exceeds quarterly expectations on surging demand for wearable insulin pumps
Insulet topped quarterly estimates behind strong demand for its wearable insulin pumps. The firm also boosted its buyback plan and set a bullish 2026 outlook.
Insights:
Insulet reported better-than-expected fourth-quarter results on February 18, 2026, driven by strong demand for its tubeless Omnipod 5 insulin pumps. The company, which is based in the United States 
US, also issued upward 2026 revenue and adjusted EPS guidance while increasing its share repurchase authorization. These developments, which occurred in a market context involving Dexcom and J.P.Morgan , materially change the company’s near-term financial metrics and announced capital return plans.
US, also issued upward 2026 revenue and adjusted EPS guidance while increasing its share repurchase authorization. These developments, which occurred in a market context involving Dexcom and J.P.Morgan , materially change the company’s near-term financial metrics and announced capital return plans.Total revenue for the fourth quarter was up 31.2% to $783.8 million. Omnipod sales in the quarter were $781.8 million, which exceeded the $767.3 million analyst estimate provided by LSEG . The company attributed these results to the strong demand for its tubeless Omnipod insulin pumps, specifically the Omnipod 5 system.
